35 results about "Monoclonal antibody 14G2A" patented technology

The invention provides isolated monoclonal antibodies that specifically bind to human Claudin 18.2. Nucleic acid molecules for encoding the antibodies, as well as expression vectors, host cells and methods for expressing the antibodies are also provided. The invention also provides immunoconjugates, bispecific molecules, chimeric antigen receptors, oncolytic viruses and pharmaceutical compositionscomprising the antibodies, and methods for diagnosis or treatment using the antibodies.

The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the grown of CD30+ cells, such as tumor cells, are also provided.

Monoclonal antibodies against gonadotropin releasing hormone (GnRH) receptor induce cellular apoptosis of various cancer cells expressing this surface receptor. The monoclonal antibodies and their humanized forms, or fragments thereof, can serve as anti-cancer agents for the treatment of cancer in humans, and can function as analogs of GnRH to affect regulation of reproductive functions or fertility in humans.

The invention provides methods for treating HIF-1a-overexpressing human tumors, inhibiting HIF-1a-overexpressing tumor invasion and preventing tumor metastasis, and / or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90a from the tumors.

The invention discloses a hybridoma cell strain capable of secreting monoclonal antibodies to quinolones and application of the monoclonal antibodies thereof. Ciprofloxacin (CIP) coupled with bovine serum albumin is used as an antigen to immunize BALB / c mice and cell fusion, screening and cloning are carried out so as to obtain one hybridoma cell strain 1F1 capable of stable passage and secretion of monoclonal antibodies (MAb) to quinolones, wherein, the accession number of the hybridoma cell strain 1F1 is CGMCC No. 5608. The titres of ascitic fluids of the 1F1 monoclonal antibodies are up to 10<-7>, and the type and the subclass of the monoclonal antibodies are IgG1 and kappa chain. According to indirect competitive ELISA analysis, the 1F1 monoclonal antibodies perform specific reactions to quinolones like ciprofloxacin, enrofloxacin, ofloxacin, danofloxacin, norfloxacin, enoxacin, marbofloxacin, sarafloxacin and difloxacin. An ELISA method, a kit and test paper for detecting residual of quinolones in food are developed by using the 1F1 monoclonal antibodies.

Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line CmA40 as deposited under American Type Culture Collection patent deposit number PTA-11304 is produced by cell fusion of a parental cell and a myeloma cell line. The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line CmA40 as deposited under American Type Culture Collection patent deposit number PTA-11304 can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.

The invention provides a hybridoma cell, PCV2 monoclonal antibody and application thereof. The present invention creatively adopts PCV2 virus-like particles as immunogens, since PCV2 virus-like particles are an empty shell structure assembled from proteins closer to normal PCV2 viruses, they can be presented to immune cells through the same way as normal virus infection Inducing the immune system to produce an immune protection response, so that the monoclonal antibody secreted by the hybridoma cells of the present invention has higher specificity and sensitivity than the PCV2 antigen protein monoclonal antibody.

The invention discloses an antihuman Her2 monoclonal antibody hybridoma cell line, monoclonal antibody, a kit and the usage. The invention can be combined with human Her2 antigen in specificity in vitro and vivo, so as to indentify the normal or the tumour cells of the human beings according to the Her2 with different levels of expression. The preservation number of the cell line is CGMCC NO.2748, and the monoclonal antibody is secreted by hybrid tumor with the preservation number of CGMCC NO.2748. The antibody is murine monoclonal antibody and belongs to IgM / x subtype. The invention adopts classic hybrid tumor preparation technology to successfully prepare the antihuman Her2 monoclonal antibody, so as to provide an effective detecting way for diagnosticating and guiding to treat tumour, especially breast cancer.

The invention relates to a chemokine-4 resisting monoclonal antibody, a chemokine-4 resisting hybridoma cell line and applications of the chemokine-4 resisting monoclonal antibody, belongs to the field of biotechnology, aims to immunize a rat by using the recombinant human CXCL4 protein, fuse the spleen cell with the myeloma cell, and screen the formed hybridoma cell and further aims to provide the application of the chemokine-4 resisting monoclonal antibody to the resistance of intestinal mucosa injury caused by chemotherapy. The monoclonal antibody provided by the invention can resist the human chemokine 4 and the rat chemokine 4 and has the effect of preventing and treating the toxic and side effects of tumor chemotherapy.

The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such as mesenchymal precursor cells (MPCs).